This technology is a topical gene-delivery platform that restores functional subunits of the adaptor protein complex-1 (AP-1) in skin cells to treat monogenic genetic skin disorders such as ichthyosis and keratoderma.
Current treatment strategies for severe inherited skin disorders, such as ichthyosis and keratoderma, involve palliative approaches that do not address underlying genetic and cellular defects. Existing gene therapy strategies for monogenic diseases are limited by risks of off-target effects, insertional oncogenesis, systemic exposure, and immune responses that prevent repeat administration. Consequently, there are no disease-modifying or curative treatments for patients with genetic skin disorders caused by defects in intracellular protein trafficking. Addressing these limitations is essential to enable safe, lasting correction of the molecular drivers of chronic skin diseases.
This technology enables localized genetic correction in the skin by delivering functional gene sequences directly to epidermal cells through topical administration. Following application to affected skin areas, the delivery system transduces epidermal cells, introducing genetic material that supplements inherited deficiencies in intracellular protein trafficking pathways critical to epidermal development and maintenance. This localized approach confines gene delivery to diseased tissue, minimizing systemic exposure while supporting repeat administration for chronic conditions. By restoring key epidermal cellular functions, the approach is designed to support improvements in skin structure and barrier maintenance associated with inherited genetic defects, offering a safe, effective, and re-administrable gene therapy platform.
Patent Pending
IR CU26038
Licensing Contact: Kristin Neuman